TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06599099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept RC System
Description: Medtronic Percept RC System includes:~Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Month Blinded Discontinuation Period
Description: The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
Study: NCT04704063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienols / Vitamin E
Description: Palm Tocotrienols complex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo matching Tocovid Suprabio
Study: NCT06655480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ARNI + SGLTi + AMR]
Description: Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Eplerenone 25-50 mg tablet
Study: NCT04654403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
Study: NCT06655480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [SGLTi + previously taken RAAS blocker]
Description: Empagliflozin 10mg tablet, previously taken RAAS inhibitor
Study: NCT06670014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeech
Description: Participants in this group will use the repeech application for a period of 4 weeks, with recommended usage of 5 days per week for 30 to 60 minutes per session. A designated speech-language pathologist (SLP) will set individualized treatment goals and customize the content of the therapy sessions based on each participant's baseline assessment. The repeech intervention will be tailored to meet the specific needs of each participant to improve speech intelligibility and communication abilities.

Intervention type: OTHER
Group type: OTHER
Intervention: Workbook
Description: Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria, due to the lack of a standardized care protocol for this condition. The recommended usage is the same as the treatment group: 5 days per week, for 30 to 60 minutes per session over a period of 4 weeks. After each self-treatment session, participants will record their activities on a checklist to monitor adherence and ensure compliance with the study protocol.
Study: NCT06670794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention for concerned partners
Description: The web-based intervention will comprise sessions focusing on community reinforcement and family therapy principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to their partner (PPR; i.e., actively listening, showing understanding, expressing interest in what their partner is thinking and feeling, and trying to see where their partner is coming from), (3) understanding their partner's drinking reinforcers, and (4) supporting their partner if they want help and engaging in positive, healthy activities with their partner.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation control
Description: This is a psychoeducation control condition.
Study: NCT06668896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
Study: NCT06669689

Intervention type: DEVICE
Intervention: operating position
Description: In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.

Intervention type: DEVICE
Intervention: operating position
Description: In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.

Intervention type: DEVICE
Intervention: pneumoperitoneum
Description: Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.

Intervention type: DEVICE
Intervention: pneumoperitoneum
Description: Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.
Study: NCT06670716

Intervention type: OTHER
Intervention: Examination by a speech therapist
Description: MASTcz test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive examination
Description: ALBA test, PICNIR test

Intervention type: OTHER
Intervention: Examination of delirium
Description: CAM-ICU and ICDSC questionnaire

Intervention type: OTHER
Intervention: History taking
Description: The first page includes several sections: personal information, pre-stroke history, time-related data, neurological deficit data, radiological evaluation, pre-admission and admission treatment, and a medical examination focused on motor and speech impairments. The third page will document the physician's delirium examination and the speech therapy assessment. A questionnaire will be given to the relatives or close persons of the patients to fill out in order to collect systematic personal and pre-stroke anamnestic data and to assess the presence of dementia signs before the stroke using the Blessed Dementia Scale (BDS) questionnaire. All pages of the record form and the Questionnaire for Relatives are included in the appendices.
Study: NCT04654403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
Study: NCT06210009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH-Style Diet
Description: Participants will be randomized to a DASH-style diet

Intervention type: OTHER
Group type: OTHER
Intervention: Western-Style Diet
Description: Participants will be randomized to a Western-style diet
Study: NCT06323928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered using subcutaneous (SC) injection.
Study: NCT04900506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior SPAIRE approach, anterior approach
Description: Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
Study: NCT06323928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered using subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered using subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered using subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered by SC injection.
Study: NCT04936620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duroplasty
Description: Expansion Duroplasty
Study: NCT04880031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection
Study: NCT04936620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal surgery
Description: Spinal surgery including laminectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal surgery
Description: Spinal surgery including laminectomy
Study: NCT04880031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection
Study: NCT05378087

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation
Description: Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation
Description: Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
Study: NCT05673187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
Study: NCT04085081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail
Description: Receive brief motivational text or email messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive personalized walking program plus strength exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive intervention coaching sessions via telephone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive brief motivational text or email messages
Study: NCT04880031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efimosfermin
Description: Efimosfermin will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection
Study: NCT05275556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Detection (CADe) Device
Description: The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
Study: NCT06520072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children Eating Well (CHEW) mobile app
Description: The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beanstalk mobile app
Description: Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,
Study: NCT06517732

Intervention type: OTHER
Intervention: Secukinumab
Description: This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Study: NCT06588322

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be taken on several times (36 mL of blood taken at each time):
Description: * Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years).
Study: NCT06670430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
Study: NCT06234046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550Mg Tab
Description: group (1) received Rifaximin as 550 mg twice daily dosage for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid sample
Description: aspiration of ascitic fluid sample and analysis for differential cell count

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid sample
Description: aspiration of ascitic fluid sample and analysis for differential cell count
Study: NCT04574778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of oral acetaminophen preoperatively administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of oral acetaminophen preoperatively administered
Study: NCT03740698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiAP
Description: The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiAP
Description: The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABC4D
Description: The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
Study: NCT06210243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C752
Description: C752 will be administered on Day 0